ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the
expression or activation of epidermal growth factor receptor and ERBB2 are altered in many …

Antineoplastic agent-induced pulmonary toxicity is an important cause of respiratory failure.
Although the incidence of antineoplastic agent-induced pulmonary toxicity seems to be low …

Introduction This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd)
monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in …

Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR)
mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors …

Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its
prevalence and risk factors remain largely unknown. We examined the prevalence of and …

Introduction It is unknown what type of interstitial lung disease (ILD) has high risk for
chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD …

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new
methods of drug delivery and pharmaceuticals have been investigated in vitro, and in …

Rationale: Noninfectious pneumonitis is a known class effect of mammalian target of
rapamycin (mTOR) inhibitors. Objectives: To assess the incidence, radiographic patterns …

Interstitial lung disease (ILD) in infants and children comprises a large spectrum of rare
respiratory disorders that are mostly chronic and associated with high morbidity and …

Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …